ZAYO-GROUP
16.1.2023 14:01:42 CET | Business Wire | Press release
Zayo Group Holdings, Inc., a leading global communications infrastructure platform, announced the deployment of a new 400G enabled route connecting Paris and Marseille—including first-in-market network hardening of this critical route leveraging next-generation fiber technologies—to provide enterprises with an easier and more secure way to transport rapidly increasing high-bandwidth traffic from these top-ten global internet hubs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005067/en/
Map of Zayo's new 400G enabled route connecting Paris and Marseille (Graphic: Business Wire)
“We are continuously expanding, improving and diversifying our network in order to support our customers with their increasing bandwidth,” said Yannick Leboyer, Europe Chief Operating Officer at Zayo. “With several new subsea cable projects set to deploy in the coming years, Marseille is on its way to becoming one of the top five internet connectivity hubs globally, and Zayo is uniquely positioned to provide the necessary infrastructure to support this growth. The Paris-to-Marseille route is built to support and transport the fast-paced bandwidth growth and increasingly high demand for connectivity in these markets, giving customers a more reliable, scalable and secure way to share data to the rest of Europe and the U.S.”
Paris is the fourth largest internet connectivity hub in the world, and Marseille, a crossroad of several major exchanges between terrestrial and submarine networks, is projected to move from the seventh to the fifth largest global internet hub in the next three years. With six new subsea cables in Marseille scheduled for completion, including key gateways to Asia, Africa and the Middle East, capacity demands in Marseille are expected to quadruple by 2026. This is creating a rapidly increasing need for enterprises to transport traffic growth from these hubs throughout Europe and to other key commerce centers across the globe.
The new Paris-to-Marseille route from Zayo provides 24 terabytes of total expected capacity per fiber pair, critical triversity options, and 400G enablement for enterprises to manage this capacity growth and ensure secure, resilient connectivity to the rest of Europe and the United States. Beyond capacity, Zayo is hardening its network with new fiber technologies, making Zayo the first carrier with this next-generation fiber on the route connecting Paris to Marseille.
The route will also provide direct access to Bordeaux—the landing city for Amitié, a new private transatlantic cable that will connect the U.S. with the UK and France. Once ready for service, the connection will enable direct access to Asia, Africa, and the Middle East.
This latest investment from Zayo is part of the company’s overall strategy to overlay its European backbone and deliver high-capacity bandwidth across Europe, following the completion of its Zeus subsea cable in 2022, which provides the strongest connection between the UK and continental Europe. To date, Zayo owns and operates 2.2 million kilometers of fiber and connects 16 key metro markets and nine countries across Europe.
To learn more about Zayo’s global network, please visit https://www.zayo.com/network/.
About Zayo Group Holdings, Inc.
Zayo Group Holdings, Inc. is the leading global communications infrastructure platform, delivering a range of solutions, including fiber & transport, packet and managed edge services. Zayo owns and operates a Tier 1 IP backbone spanning 137,000 miles across North America and Europe. By providing this mission-critical bandwidth to its category-leading customers across the wireless, hyperscale, media, tech and finance industries, Zayo is fueling the innovations that are transforming society. For more information, visit https://zayo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
